Clinical Trials Logo

Clinical Trial Summary

This study examines how supportive care clinic patients have made decisions or had discussions about how their caregivers or family should manage their social media account(s) after death. Collecting information on the use of social media and preferences will allow for a better understanding of patient's needs in the dying process and may identify populations in need of education, identify a possible source of anxiety and stress, and allow for an informed discussion of digital legacy.


Clinical Trial Description

PRIMARY OBJECTIVE: I. Identify the proportion of patients with advanced cancer in the supportive cancer clinic who have had discussions regarding their social media account (e.g. Facebook, Twitter, Instagram) management after death. SECONDARY OBJECTIVE: I. Identify the proportion of social media participation among advanced cancer patients seen in the supportive care clinic. II. Evaluate the baseline awareness advanced cancer patients seen in the supportive care clinic have regarding how their Facebook account may be managed after death. III. Evaluate affect changes and distress as a result from the conversation regarding their social media account management after death. IV. Evaluate if discussion of social media account management among patients with advanced cancer in the supportive cancer clinic will increase their awareness of and motivation to address their social media account management options. OUTLINE: Patients complete questionnaires over 30 minutes about level of anxiety and social media use and management. ;


Study Design


Related Conditions & MeSH terms

  • Advanced Malignant Solid Neoplasm
  • Hematopoietic and Lymphoid System Neoplasm
  • Neoplasms

NCT number NCT05035667
Study type Observational
Source M.D. Anderson Cancer Center
Contact
Status Recruiting
Phase
Start date December 22, 2020
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05039801 - IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors Phase 1
Suspended NCT03253679 - AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification Phase 2
Withdrawn NCT03925428 - Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas Phase 1
Not yet recruiting NCT05039632 - NBTXR3, Radiation Therapy, Ipilimumab, and Nivolumab for the Treatment of Lung and/or Liver Metastases From Solid Malignancy Phase 1/Phase 2
Recruiting NCT02389309 - Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors Phase 1
Recruiting NCT03065387 - Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Phase 1
Active, not recruiting NCT04552704 - CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study Phase 1/Phase 2
Not yet recruiting NCT04939090 - Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients Phase 3
Not yet recruiting NCT05038839 - Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors Phase 1
Active, not recruiting NCT03698994 - Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT03210714 - Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT02451553 - Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer Phase 1
Recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Not yet recruiting NCT04090619 - Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers
Active, not recruiting NCT01480154 - Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Phase 1
Completed NCT03291938 - IACS-010759 in Advanced Cancers Phase 1
Recruiting NCT01434316 - Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04439344 - Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) Phase 2
Active, not recruiting NCT04439201 - Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) Phase 2
Active, not recruiting NCT04439123 - Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) Phase 2